Author: Okazaki, Shunichiro; Nagoya, Satoshi; Matsumoto, Hiroshi; Mizuo, Keisuke; Sasaki, Mikito; Watanabe, Satoshi; Yamashita, Toshihiko; Inoue, Hiromasa
Title: Development of non-traumatic osteonecrosis of the femoral head requires toll-like receptor 7 and 9 stimulations and is boosted by repression on nuclear factor kappa B in rats Document date: 2014_11_10
ID: r5hqj5ib_20
Snippet: dose-dependent manner. In the groups co-administered 5 or 10 mg/kg BAY11-7082, no ONFH was observed after MPSL treatment. The incidence of ONFH in the group co-administered 5 mg/kg BAY11-7082 was significantly less than that in the Imiquimod þ MPSL group (P ¼ 0.01; Fisher's exact test). However, 1 of 10 rats died within 7 days after the administration of 1, 3, or 5 mg/kg BAY11-7082, and 3 of 6 rats died within 7 days after the administration of.....
Document: dose-dependent manner. In the groups co-administered 5 or 10 mg/kg BAY11-7082, no ONFH was observed after MPSL treatment. The incidence of ONFH in the group co-administered 5 mg/kg BAY11-7082 was significantly less than that in the Imiquimod þ MPSL group (P ¼ 0.01; Fisher's exact test). However, 1 of 10 rats died within 7 days after the administration of 1, 3, or 5 mg/kg BAY11-7082, and 3 of 6 rats died within 7 days after the administration of 10 mg/kg BAY11-7082. Owing to the high mortality observed in the BAY11-7082 group, no further experiments were performed using these rats. Figure 4 shows the activity of NF-kB and IRF7 in the liver at 24 h after MPSL treatment in Imiquimod þ MPSL (n ¼ 8)
Search related documents:
Co phrase search for related documents- dose dependent manner and high mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- exact test and Fisher exact test: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- exact test and group onfh incidence: 1
- exact test and high mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- exact test and Imiquimod þ MPSL group: 1
- exact test and onfh incidence: 1
- Fisher exact test and high mortality: 1, 2, 3
- group onfh incidence and Imiquimod þ MPSL group: 1, 2, 3
- group onfh incidence and MPSL treatment: 1, 2, 3
- group onfh incidence and onfh incidence: 1, 2, 3, 4, 5, 6
- Imiquimod þ MPSL group and MPSL treatment: 1, 2, 3
- Imiquimod þ MPSL group and onfh incidence: 1, 2, 3, 4
- Imiquimod þ MPSL MPSL treatment and MPSL treatment: 1
- Imiquimod þ MPSL MPSL treatment and onfh incidence: 1
- MPSL treatment and onfh incidence: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date